Search

Your search keyword '"Klaiber, Ulla"' showing total 273 results
Start Over Author "Klaiber, Ulla"
273 results on '"Klaiber, Ulla"'

10. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study

Author

van Veldhuisen, Eran, Klompmaker, Sjors, Janssen, Quisette P., Hilal, Mohammed Abu, Alseidi, Adnan, Balduzzi, Alberto, Balzano, Gianpaolo, Bassi, Claudio, Berrevoet, Frederik, Bonds, Morgan, Busch, Olivier R., Butturini, Giovanni, Conlon, Kevin C., Frigerio, Isabella M., Fusai, Giuseppe K., Gagnière, Johan, Griffin, Oonagh, Hackert, Thilo, Halimi, Asif, Keck, Tobias, Kleeff, Jörg, Klaiber, Ulla, Labori, Knut J., Lesurtel, Mickael, Malleo, Giuseppe, Marino, Marco V., Molenaar, I. Quintus, Mortensen, Michael B., Nikov, Andrej, Pagnanelli, Michele, Pandé, Rupaly, Pfeiffer, Per, Pietrasz, Daniel, Rangelova, Elena, Roberts, Keith J., Cunha, Antonio Sa, Salvia, Roberto, Strobel, Oliver, Tarvainen, Timo, Wilmink, Johanna W., Koerkamp, Bas Groot, and Besselink, Marc G.

Published
2023
Full Text
View/download PDF

26. Safety of multimodality treatment with a combination of intra- operative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: The combiCaRe study

Author

Roth, Susanne, primary, Cal y Mayor, Mariana Buenrostro, additional, Alhalabi, Karam T., additional, Springfeld, Christoph, additional, Diener, Markus, additional, Tjaden, Christine, additional, Knebel, Phillip, additional, Klaiber, Ulla, additional, Mieth, Markus, additional, Michalski, Christoph, additional, Jäger, Dirk, additional, Büchler, Markus W., additional, and Hackert, Thilo, additional

Published
2023
Full Text
View/download PDF

31. Protocol of a randomised controlled phase II clinical trial investigating PREoperative endoscopic injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection: the PREBOT-II trial

Author

Mack, Claudia Eva, primary, Klaiber, Ulla, additional, Sauer, Peter, additional, Kohlhas, Laura, additional, Baumann, Lukas, additional, Martin, Eike, additional, Mehrabi, Arianeb, additional, Buchler, Markus W, additional, and Hackert, Thilo, additional

Published
2023
Full Text
View/download PDF

32. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis.

Author

Leonhardt, Carl-Stephan, Hank, Thomas, Pils, Dietmar, Gustorff, Charlotte, Sahora, Klaus, Schindl, Martin, Verbeke, Caroline S., Strobel, Oliver, and Klaiber, Ulla

Abstract

Background: A greater than 1 mm tumour-free resection margin (R0 > 1 mm) is a prognostic factor in upfront-resected pancreatic ductal adenocarcinoma. After neoadjuvant treatment (NAT); however, the prognostic impact of resection margin (R) status remains controversial. Methods: Randomised and non-randomised studies assessing the association of R status and survival in resected pancreatic ductal adenocarcinoma after NAT were sought by systematic searches of MEDLINE, Web of Science and CENTRAL. Hazard ratios (HR) and their corresponding 95% CI were collected to generate log HR using the inverse-variance method. Random-effects metaanalyses were performed and the results presented as weighted HR. Sensitivity and meta-regression analyses were conducted to account for different surgical procedures and varying length of follow-up, respectively. Results: Twenty-two studies with a total of 4929 patients were included. Based on univariable data, R0 greater than 1 mm was significantly associated with prolonged overall survival (OS) (HR 1.76, 95% CI 1.57-1.97; P<0.00001) and disease-free survival (DFS) (HR 1.66, 95% CI 1.39-1.97; P< 0.00001). Using adjusted data, R0 greater than 1 mm was significantly associated with prolonged OS (HR 1.65, 95% CI 1.39-1.97; P<0.00001) and DFS (HR 1.76, 95% CI 1.30-2.39; P =0.0003). Results for R1 direct were comparable in the entire cohort; however, no prognostic impact was detected in sensitivity analysis including only partial pancreatoduodenectomies. Conclusion: After NAT, a tumour-free margin greater than 1 mm is independently associated with improved OS as well as DFS in patients undergoing surgical resection for pancreatic cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment

Author

Leonhardt, Carl-Stephan, primary, Pils, Dietmar, additional, Qadan, Motaz, additional, Jomrich, Gerd, additional, Assawasirisin, Charnwit, additional, Klaiber, Ulla, additional, Sahora, Klaus, additional, Warshaw, Andrew L., additional, Ferrone, Cristina R., additional, Schindl, Martin, additional, Lillemoe, Keith D., additional, Strobel, Oliver, additional, Fernández-del Castillo, Carlos, additional, and Hank, Thomas, additional

Published
2023
Full Text
View/download PDF

39. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer:An International Multicenter Cohort Study

Author

van Veldhuisen, Eran, Klompmaker, Sjors, Janssen, Quisette P., Hilal, Mohammed Abu, Alseidi, Adnan, Balduzzi, Alberto, Balzano, Gianpaolo, Bassi, Claudio, Berrevoet, Frederik, Bonds, Morgan, Busch, Olivier R., Butturini, Giovanni, Conlon, Kevin C., Frigerio, Isabella M., Fusai, Giuseppe K., Gagnière, Johan, Griffin, Oonagh, Hackert, Thilo, Halimi, Asif, Keck, Tobias, Kleeff, Jörg, Klaiber, Ulla, Labori, Knut J., Lesurtel, Mickael, Malleo, Giuseppe, Marino, Marco V., Molenaar, I. Quintus, Mortensen, Michael B., Nikov, Andrej, Pagnanelli, Michele, Pandé, Rupaly, Pfeiffer, Per, Pietrasz, Daniel, Rangelova, Elena, Roberts, Keith J., Cunha, Antonio Sa, Salvia, Roberto, Strobel, Oliver, Tarvainen, Timo, Wilmink, Johanna W., Koerkamp, Bas Groot, Besselink, Marc G., Sauvanet, Alain, Marthey, Lysiane, Laurent, Christophe, Régenet, Nicolas, Coriat, Romain, Taieb, Julien, Turini, Olivier, van Veldhuisen, Eran, Klompmaker, Sjors, Janssen, Quisette P., Hilal, Mohammed Abu, Alseidi, Adnan, Balduzzi, Alberto, Balzano, Gianpaolo, Bassi, Claudio, Berrevoet, Frederik, Bonds, Morgan, Busch, Olivier R., Butturini, Giovanni, Conlon, Kevin C., Frigerio, Isabella M., Fusai, Giuseppe K., Gagnière, Johan, Griffin, Oonagh, Hackert, Thilo, Halimi, Asif, Keck, Tobias, Kleeff, Jörg, Klaiber, Ulla, Labori, Knut J., Lesurtel, Mickael, Malleo, Giuseppe, Marino, Marco V., Molenaar, I. Quintus, Mortensen, Michael B., Nikov, Andrej, Pagnanelli, Michele, Pandé, Rupaly, Pfeiffer, Per, Pietrasz, Daniel, Rangelova, Elena, Roberts, Keith J., Cunha, Antonio Sa, Salvia, Roberto, Strobel, Oliver, Tarvainen, Timo, Wilmink, Johanna W., Koerkamp, Bas Groot, Besselink, Marc G., Sauvanet, Alain, Marthey, Lysiane, Laurent, Christophe, Régenet, Nicolas, Coriat, Romain, Taieb, Julien, and Turini, Olivier

Abstract

Background. Preoperative FOLFIRINOX chemotherapy is increasingly administered to patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) to improve overall survival (OS). Multicenter studies reporting on the impact from the number of preoperative cycles and the use of adjuvant chemotherapy in relation to outcomes in this setting are lacking. This study aimed to assess the outcome of pancreatectomy after preoperative FOLFIRINOX, including predictors of OS.Methods. This international multicenter retrospective cohort study included patients from 31 centers in 19 European countries and the United States undergoing pancreatectomy after preoperative FOLFIRINOX chemotherapy (2012-2016). The primary end point was OS from diagnosis. Survival was assessed using Kaplan-Meier analysis and Cox regression.Results. The study included 423 patients who underwent pancreatectomy after a median of six (IQR 5-8) preoperative cycles of FOLFIRINOX. Postoperative major morbidity occurred for 88 (20.8%) patients and 90-day mortality for 12 (2.8%) patients. An R0 resection was achieved for 243 (57.4%) patients, and 259 (61.2%) patients received adjuvant chemotherapy. The median OS was 38 months (95% confidence interval [CI] 34-42 months) for BRPC and 33 months (95% CI 27-45 months) for LAPC. Overall survival was significantly associated with R0 resection (hazard ratio [HR] 1.63; 95% CI 1.20-2.20) and tumor differentiation (HR 1.43; 95% CI 1.08-1.91). Neither the number of preoperative chemotherapy cycles nor the use adjuvant chemotherapy was associated with OS.Conclusions. This international multicenter study found that pancreatectomy after FOLFIRINOX chemotherapy is associated with favorable outcomes for patients with BRPC and those with LAPC. Future studies should confirm that the number of neoadjuvant cycles and the use adjuvant chemotherapy have no relation to OS after resection.

Published
2023

42. Conflicts of interest in randomised controlled surgical trials: systematic review and qualitative and quantitative analysis

Author

Probst Pascal, Grummich Kathrin, Klaiber Ulla, Knebel Phillip, Ulrich Alexis, Büchler Markus W., and Diener Markus K.

Subjects
conflicting interest, critical appraisal, industry bias, secondary interest, study validity, Surgery, RD1-811
Abstract

Conflicts of interest may lead to biased trial designs and unbalanced interpretation of study results. We aimed to evaluate the reporting of potential conflicts of interest in full publications of surgical randomised controlled trials (RCTs). A systematic literature search was performed in CENTRAL, MEDLINE and EMBASE (1985–2014) to find all surgical RCTs of medical devices and perioperative pharmacological or nutritional interventions. The information on conflicts of interest was evaluated both quantitatively and qualitatively, and the development of stated conflicts over time was studied. Of 7934 articles, 444 met the inclusion criteria. In 93 of 444 trials (20.9%), conflicts of interest were disclosed. In half of the cases, the information provided was insufficient to permit conclusions regarding possible influence on the trials. Information about conflicts of interest has increased continuously during the last decades (1985–1994: 0%, 1995–2004: 2.8% and 2005–2014: 33.0%; p

Published
2016
Full Text
View/download PDF

45. Central pancreatectomy prevents postoperative diabetes

Author

Klotz, Rosa, primary, Schilling, Constanze, additional, Kuner, Charlotte, additional, Hinz, Ulf, additional, Klaiber, Ulla, additional, Holze, Magdalena, additional, Tjaden, Christine, additional, Loos, Martin, additional, Büchler, Markus W., additional, and Hackert, Thilo, additional

Published
2022
Full Text
View/download PDF

46. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study

Author

Leonhardt, Carl-Stephan, primary, Kinny-Köster, Benedict, additional, Hank, Thomas, additional, Habib, Joseph R., additional, Shoucair, Sami, additional, Klaiber, Ulla, additional, Cameron, John L., additional, Hackert, Thilo, additional, Wolfgang, Christopher L., additional, Büchler, Markus W., additional, He, Jin, additional, and Strobel, Oliver, additional

Published
2022
Full Text
View/download PDF

47. Central pancreatectomy prevents postoperative diabetes.

Author

Klotz, Rosa, Schilling, Constanze, Kuner, Charlotte, Hinz, Ulf, Klaiber, Ulla, Holze, Magdalena, Tjaden, Christine, Loos, Martin, Büchler, Markus W., and Hackert, Thilo

Abstract

Background: Central pancreatectomy (CP) can be performed as an alternative surgical approach to distal pancreatectomy (DP) in the treatment of benign or low‐grade malignant lesions located in the neck and body of the pancreas, aiming to reduce loss of parenchyma and therefore organ failure. The objective of this study was to evaluate the short‐ and long‐term outcome of CP in comparison to DP. Methods: Patients who received CP in a large tertiary care pancreatic surgery center between 2001 and 2020 were identified from a prospectively maintained database and compared via propensity score matching with patients receiving DP during the same time period. Perioperative rate of complications and long‐term outcome of pancreatic endocrine and exocrine function were evaluated. Results: One hundred and seven patients undergoing open CP were compared to 107 patients with open DP. No significant difference in rates or severity of most surgical complications could be found including postoperative pancreatic fistula, intraabdominal fluid collection, delayed gastric emptying and wound infection. However, patients receiving CP had a significantly higher risk of grade C postpancreatectomy hemorrhage (PPH) (CP: 10 patients, 9.3% versus DP: 1 patient, 0.9%; p =.0019). Perioperative mortality was comparable. Long‐term follow‐up of 60 matched pairs revealed significantly less patients with new‐onset diabetes after CP (eight patients, 13.3%) compared to DP (22 patients, 36.7%, p =.0056). Conclusion: CP offers an improved endocrine long‐term outcome at the expense of a higher risk of PPH without increased perioperative mortality. As evidence on this parenchyma sparing surgical technique is sparse, more prospective data are needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival

Author

Hackert, Thilo, primary, Klaiber, Ulla, additional, Hinz, Ulf, additional, Strunk, Susanne, additional, Loos, Martin, additional, Strobel, Oliver, additional, Berchtold, Christoph, additional, Kulu, Yakup, additional, Mehrabi, Arianeb, additional, Müller-Stich, Beat P., additional, Schneider, Martin, additional, and Büchler, Markus W., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results